Literature DB >> 11378877

1H NMR visible lipids are induced by phosphonium salts and 5-fluorouracil in human breast cancer cells.

W A Cooper1, W A Bartier, D C Rideout, E J Delikatny.   

Abstract

Cationic lipophilic phosphonium salts (CLPS) selectively accumulate in the mitochondria of neoplastic cells and inhibit mitochondrial function. The effects of the CLPS p-(triphenylphosphoniummethyl) benzaldehyde chloride (drug A), and [4-(hydrazinocarboxy)-1-butyl] tris-(4-dimethylaminophenyl) phosphonium chloride (drug B), on human breast cells of differing biological properties were assessed using growth inhibition assays and 1H NMR. Drug A and, to a lesser extent, drug B demonstrated selective growth inhibition of the highly tumorigenic DU4475 breast carcinoma cell line compared to the transformed HBL-100 human breast cell line. However, in contrast to previous studies using other cell lines, no synergistic activity was found when the drugs were used in combination. 1H NMR demonstrated significant increases in mobile lipid acyl chain resonances in both cell lines treated with cytotoxic doses (IC50, 48 h) of the drugs used either alone or in combination. Two-dimensional NMR revealed accompanying decreases in phosphocholine/Lys levels in HBL-100 cells treated with A, B, or a 1:1 combination A+B at the IC50, and in DU4475 cells treated with drug A (IC50). This was accompanied by significant increases in cho/Lys ratios with IC50 A or combination A+B treatment. Similar spectra were observed in cells treated with 5-fluorouracil but not methotrexate, indicating that mobile lipid accumulation is a general but not universal response to cytotoxic insult. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378877     DOI: 10.1002/mrm.1133

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  8 in total

Review 1.  MR-visible lipids and the tumor microenvironment.

Authors:  E James Delikatny; Sanjeev Chawla; Daniel-Joseph Leung; Harish Poptani
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

2.  Phosphonium lipocations as antiparasitic agents.

Authors:  Timothy E Long; Xiao Lu; Melina Galizzi; Roberto Docampo; Jiri Gut; Philip J Rosenthal
Journal:  Bioorg Med Chem Lett       Date:  2012-02-23       Impact factor: 2.823

3.  (2-Hy-droxy-eth-yl)triphenyl-phospho-nium chloride.

Authors:  Umit Ceylan; Hasan Tanak; Ercan Türkkan; Omer Dereli; Orhan Büyükgüngör
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-02-16

4.  Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activity.

Authors:  Melissa Millard; Divya Pathania; Yumna Shabaik; Laleh Taheri; Jinxia Deng; Nouri Neamati
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

5.  Lipid accumulation facilitates mitotic slippage-induced adaptation to anti-mitotic drug treatment.

Authors:  Alex Wong; Sixun Chen; Lay Kien Yang; Yoganathan Kanagasundaram; Karen Crasta
Journal:  Cell Death Discov       Date:  2018-11-27

6.  NMR spectroscopy of macrophages loaded with native, oxidized or enzymatically degraded lipoproteins.

Authors:  Paul Ramm Sander; Markus Peer; Margot Grandl; Ulrich Bogdahn; Gerd Schmitz; Hans Robert Kalbitzer
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

7.  High Cytotoxic Activity of Phosphonium Salts and Their Complementary Selectivity towards HeLa and K562 Cancer Cells: Identification of Tri-n-butyl-n-hexadecylphosphonium bromide as a Highly Potent Anti-HeLa Phosphonium Salt.

Authors:  Barbara Bachowska; Julia Kazmierczak-Baranska; Marcin Cieslak; Barbara Nawrot; Dorota Szczęsna; Joanna Skalik; Piotr Bałczewski
Journal:  ChemistryOpen       Date:  2012-02-17       Impact factor: 2.911

8.  Fast 2D NMR Spectroscopy for In vivo Monitoring of Bacterial Metabolism in Complex Mixtures.

Authors:  Rupashree Dass; Katarzyna Grudzia Ż; Takao Ishikawa; Michał Nowakowski; Renata Dȩbowska; Krzysztof Kazimierczuk
Journal:  Front Microbiol       Date:  2017-07-14       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.